MedTrace Logo

Epigenetic Biomarker for Osteosarcoma

NCT03336554 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-11-13

No results posted yet for this study

Summary

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma.

Conditions

  • Histologic Response (Tumor Necrosis Rate)
  • Objective Response Rate for Neoadjuvant Chemotherapy, ORR
  • Progression-free Survival, PFS
  • Overall Survival, OS

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo, M.D.and Ph.D. · Musculoskeletal Tumor Center of Peking University People's Hospital

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-10-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336554 on ClinicalTrials.gov